GILEAD

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 (GILEAD)

The primary objective of this study is to evaluate whether remdesivir (RDV) reduces the risk of death through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19)